
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Writing the NIH Grant Proposal: Chapter 5 - Part I (Application Writing)</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Writing the NIH Grant Proposal: Chapter 5 - Part I (Application Writing)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Writing the NIH Grant Proposal: A Step-by-Step Guide</em> (SAGE Publications, 2018)</li>
<li style="margin-left: 0px;">Topic: NIH Grant Application Writing - Approach Section &amp; Innovation</li>
<li style="margin-left: 0px;">Author(s): William Gerin, Christine Kapelewski Kinkade, Niki L. Page</li>
</ul>
<details><summary><strong>1. Understanding Innovation in NIH Proposals</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>1.1 NIH Definition of Innovation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Innovation</strong> challenges current research/clinical practice paradigms using novel theoretical concepts, approaches, methodologies, instrumentation, or interventions</li>
<li style="margin-left: 0px;">Can be <strong>novel to one field</strong> OR <strong>novel in a broad sense</strong></li>
<li style="margin-left: 0px;">May involve refinement, improvement, or new application of existing concepts</li>
</ul>
</div></details>
<details><summary><strong>1.2 Four Categories of Innovation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>New Idea</strong>: Underlying concept already tested in several studies (less innovative)</li>
<li style="margin-left: 0px;"><strong>New Population</strong>: Studying understudied populations—sex (women), race/ethnicity (minorities at greater risk for illness)</li>
<li style="margin-left: 0px;"><strong>Novel Technology/Statistics</strong>: New devices or statistical methods showing promise over previous approaches</li>
<li style="margin-left: 0px;"><strong>Untested Methodological Improvements</strong>: Larger sample size, longer follow-up duration</li>
</ul>
</div></details>
<details><summary><strong>1.3 Key Insight: Simplification vs. Complexity</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Science proposed is inevitably a simplification of complex reality</li>
<li style="margin-left: 0px;">Must acknowledge complexities without getting sidetracked</li>
<li style="margin-left: 0px;">Avoid over-complication that prevents completion</li>
<li style="margin-left: 0px;"><strong>Writing principle</strong>: Be ruthless with prose—cut anything that doesn&#x27;t advance the story</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. The Approach Section: Overview</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Purpose and Structure</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Describes <strong>methodology</strong> to address Specific Aims</li>
<li style="margin-left: 0px;">Typically 8–9 pages in length</li>
<li style="margin-left: 0px;">Two main components:</li>
<li style="margin-left: 20px;">Preliminary Studies (new application) OR Progress Report (renewal/revision)</li>
<li style="margin-left: 20px;">Research Methods and Design</li>
</ul>
</div></details>
<details><summary><strong>2.2 Preliminary Studies Section</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Demonstrates <strong>capabilities</strong> to carry out proposed research</li>
<li style="margin-left: 0px;">Showcases <strong>pilot data</strong> supporting hypotheses</li>
<li style="margin-left: 0px;">For new applications: presents Preliminary Studies (not Progress Report)</li>
</ul>
</div></details>
<details><summary><strong>2.3 What to Include in Preliminary Studies</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Team Skills</strong>: Research abstracts demonstrating competence in relevant areas (e.g., heart rate variability, baroreflex sensitivity expertise)</li>
<li style="margin-left: 0px;"><strong>Pilot Data</strong>: Direct data bearing on research question—more important for R01 than K awards or R21</li>
<li style="margin-left: 0px;"><strong>Experience</strong>: Any team member&#x27;s data supporting capabilities becomes part of PI&#x27;s experience</li>
</ul>
</div></details>
<details><summary><strong>2.4 Pilot Data Importance by Grant Mechanism</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>R01</strong>: Crucial—provides evidence for: (1) research experience, (2) project feasibility, (3) hypothesis support</li>
<li style="margin-left: 0px;"><strong>R21</strong>: Less required (exploratory), but still recommended—may be reviewed with R01 applications</li>
<li style="margin-left: 0px;"><strong>Recommendation</strong>: Always obtain feasibility data, even on few subjects</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Preliminary Studies Example: Detailed Breakdown</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Dr. Okata&#x27;s Current Trial (Subject Recruitment)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Site PI: Dr. Okata at New York Medical Center (NYMC)</li>
<li style="margin-left: 0px;"><strong>Current trial</strong>: RCT testing stress management intervention on BP in hypertensives</li>
<li style="margin-left: 0px;"><strong>Recruitment details</strong>:</li>
<li style="margin-left: 20px;">10 community health centers</li>
<li style="margin-left: 20px;">Screened ~6,000 people (460 average per screening)</li>
<li style="margin-left: 20px;">HTN prevalence: <strong>22%</strong></li>
<li style="margin-left: 20px;">Refusal rate at screening: <strong>~14%</strong></li>
<li style="margin-left: 20px;">Enrollment rate of eligible: <strong>55%</strong></li>
<li style="margin-left: 20px;">Target total: 400 hypertensives by October 2007</li>
<li style="margin-left: 20px;">Retention rate: <strong>~90%</strong> at 12-month follow-up</li>
</ul>
</div></details>
<details><summary><strong>3.2 Dr. Ruggiero&#x27;s Expertise (Cardiovascular Autonomic Control)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Published studies on psychological factors and autonomic control using spectral power analysis</li>
<li style="margin-left: 0px;">Laboratory and ambulatory settings (24-hour Holter monitoring)</li>
<li style="margin-left: 0px;">Published in <em>Journal of Important Psychophysiological Results</em> (2005)</li>
<li style="margin-left: 0px;">Will supervise laboratory procedures for baroreceptor sensitivity assessment</li>
</ul>
</div></details>
<details><summary><strong>3.3 Pilot Study: Guided Breathing Trial</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Sample</strong>: 5 hypertensive patients (3 male, 2 female)</li>
<li style="margin-left: 0px;"><strong>Design</strong>: Open-label trial, no control condition</li>
<li style="margin-left: 0px;"><strong>Procedure</strong>: </li>
<li style="margin-left: 20px;">Baseline 24-hour ABP monitoring</li>
<li style="margin-left: 20px;">Guided breathing technique training (15 min/day for 8 weeks)</li>
<li style="margin-left: 20px;">Repeat ABP monitoring at 8 weeks</li>
<li style="margin-left: 0px;"><strong>Results</strong>: Mean SBP/DBP reduction of <strong>11.6/5.4 mmHg</strong></li>
<li style="margin-left: 0px;">3 of 5 patients showed clinically significant reduction (&gt;5 mmHg SBP)</li>
<li style="margin-left: 0px;">Supports primary hypothesis that guided breathing reduces 24-hour BP</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Research Methods and Design: Core Elements</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Essential Components</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Overall strategy, methodology, analyses to accomplish Specific Aims</li>
<li style="margin-left: 0px;">Data collection, analysis, and interpretation methods</li>
<li style="margin-left: 0px;">Resource-sharing plans as appropriate</li>
<li style="margin-left: 0px;">Potential problems, alternative strategies, benchmarks for success</li>
<li style="margin-left: 0px;">Early-stage development: feasibility strategy and high-risk management</li>
<li style="margin-left: 0px;">Safety precautions (hazardous materials, select agents)</li>
</ul>
</div></details>
<details><summary><strong>4.2 Detailed Requirements Checklist</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Study design with strengths/advantages and alternatives</li>
<li style="margin-left: 0px;">Population characteristics, inclusion/exclusion criteria</li>
<li style="margin-left: 0px;">Informed consent procedures</li>
<li style="margin-left: 0px;">Recruitment/attrition plan with flowchart and backup plan</li>
<li style="margin-left: 0px;">Sample size and power calculations for each primary hypothesis</li>
<li style="margin-left: 0px;">Manipulation, intervention, independent variables, control conditions</li>
<li style="margin-left: 0px;">Outcome descriptions</li>
<li style="margin-left: 0px;">Procedures with quality control measures</li>
<li style="margin-left: 0px;">Randomization method (stratification, matching considerations)</li>
<li style="margin-left: 0px;">Study timeline</li>
<li style="margin-left: 0px;">Measures used in study</li>
<li style="margin-left: 0px;">Data management and missing values handling</li>
<li style="margin-left: 0px;">Statistical analysis approach</li>
<li style="margin-left: 0px;">Dissemination of results</li>
<li style="margin-left: 0px;">Potential limitations and solutions</li>
</ul>
</div></details>
<details><summary><strong>4.3 Writing Guidance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Must include exhaustive methodological detail despite 12-page limit</li>
<li style="margin-left: 0px;">Cut unnecessary phrases, sentences, paragraphs—revise repeatedly</li>
<li style="margin-left: 0px;">Maintain natural flow and readability even in methodological detail</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Study Design Example: Guided Breathing RCT</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Overview and Design Structure</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>RCT with four conditions</strong>:</li>
<li style="margin-left: 20px;">Standard duration treatment (N = 80)</li>
<li style="margin-left: 20px;">Extended duration treatment (N = 80)</li>
<li style="margin-left: 20px;">Placebo control (N = 80)</li>
<li style="margin-left: 20px;">Usual care control (N = 80)</li>
<li style="margin-left: 0px;"><strong>Design</strong>: Mixed design—within-subjects (change in ABP) × between-subjects (conditions)</li>
</ul>
</div></details>
<details><summary><strong>5.2 Condition Details</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Standard Duration</strong>: Device used during first 8 weeks only, then discontinued</li>
<li style="margin-left: 0px;"><strong>Extended Duration</strong>: Device used throughout entire 12-month period</li>
<li style="margin-left: 0px;"><strong>Placebo</strong>: Identical device appearance, but plays random musical tones (not guided to 6–10 breaths/min)—creates 15-minute relaxation period; use ends at 8 weeks</li>
<li style="margin-left: 0px;"><strong>Usual Care</strong>: No device given</li>
</ul>
</div></details>
<details><summary><strong>5.3 Intervention: Device-Guided Breathing</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Device: Respirco (Taos, NM) guides breathing to 6 breaths/minute</li>
<li style="margin-left: 0px;">Manufacturer reprogrammed devices for placebo condition (see letter in Chapter 7)</li>
<li style="margin-left: 0px;">Placebo device allows evaluation of: (a) relaxation effect on BP, (b) guided breathing effect over and above relaxation</li>
</ul>
</div></details>
<details><summary><strong>5.4 Primary and Secondary Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary outcome</strong>: Difference between conditions in ABP change from baseline to 8 weeks</li>
<li style="margin-left: 0px;"><strong>Secondary outcome</strong>: Difference between conditions in ABP change from baseline to 12 months</li>
<li style="margin-left: 0px;"><strong>Additional outcomes</strong>: Ambulatory respiration rate, HRV, baroreflex sensitivity, self-report measures (activity level, anxiety)</li>
</ul>
</div></details>
<details><summary><strong>5.5 Hypotheses</strong></summary><div style="padding-left: 20px;">
<p><strong>Primary (8 weeks)</strong>:</p>
<p>1. Intervention conditions will have lower ABP vs. UC and placebo</p>
<p>2.</p>
</div></details>
</div></details>
<details><summary><strong>1. Design Considerations and Methodological Justifications</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>1.1 Why Not Use a Crossover Design</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Considered but rejected for this study</li>
<li style="margin-left: 0px;"><strong>Crossover design useful when</strong>: no possibility of carryover effects</li>
<li style="margin-left: 0px;"><strong>Problem</strong>: Study specifically interested in testing carryover effects (extended duration intervention)</li>
<li style="margin-left: 0px;">Crossover design would not allow testing of primary and secondary hypotheses</li>
</ul>
</div></details>
<details><summary><strong>1.2 Usual Care Control Condition Complexity</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">All RCTs face challenge designing control conditions</li>
<li style="margin-left: 0px;">Simply participating in trial often affects patient behavior</li>
<li style="margin-left: 0px;"><strong>Decision</strong>: Use home BP monitoring in UC condition as compromise</li>
<li style="margin-left: 0px;">Must have comparable measures across conditions to understand processes</li>
<li style="margin-left: 0px;">Does not wish to impinge on that effect</li>
<li style="margin-left: 0px;"><strong>Note</strong>: &quot;UC condition is not really usual care&quot;—subjects aware they are in trial; contact and measurements reinforce awareness</li>
<li style="margin-left: 0px;">Trial is <strong>efficacy</strong> (not effectiveness) trial—current configuration best compromise</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Participant Recruitment, Eligibility, and Study Procedures</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Clinical Sites and Population</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>NYMC</strong>: Tertiary care teaching facility and medical school</li>
<li style="margin-left: 0px;">Draws patients from greater New York metropolitan area</li>
<li style="margin-left: 0px;">22 community health centers under NYMC umbrella—study uses 12</li>
<li style="margin-left: 0px;"><strong>Patient population demographics</strong>:</li>
<li style="margin-left: 20px;">Caucasian: 35%</li>
<li style="margin-left: 20px;">African American: 29%</li>
<li style="margin-left: 20px;">Latino: 19%</li>
<li style="margin-left: 20px;">Asian: 16%</li>
<li style="margin-left: 0px;">Total annual visits: <strong>46,000</strong></li>
<li style="margin-left: 0px;">Letters of Agreement section contains 12 site letters</li>
</ul>
</div></details>
<details><summary><strong>2.2 Physician Referrals and Recruitment Strategy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">12 referring physicians (one at each site)</li>
<li style="margin-left: 0px;">Total patient visits/year: <strong>52,800</strong></li>
<li style="margin-left: 0px;">New patients/week: 15–20</li>
<li style="margin-left: 0px;"><strong>Recruitment goal</strong>: 692 patients over 4-year period</li>
<li style="margin-left: 0px;">Using strategy successful in Dr. Okata&#x27;s current trial in same population</li>
</ul>
</div></details>
<details><summary><strong>2.3 Screening Process</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Anticipated HTN prevalence at screening (SBP &gt;140 or DBP &gt;90 mmHg): <strong>~30%</strong></li>
<li style="margin-left: 0px;">More than 40% of hypertensive screening BP are African American (overrepresented)</li>
<li style="margin-left: 0px;">Experience suggests: 15% with screening BP in hypertensive range will have normal BP when assessed using ABP</li>
<li style="margin-left: 0px;"><strong>Screening calculation</strong>:</li>
<li style="margin-left: 20px;">Total to screen: 1,960 participants (12 screening periods × 163 average per period)</li>
<li style="margin-left: 20px;">BP &gt;140/90 mmHg: ~588</li>
<li style="margin-left: 20px;">Remain hypertensive by ABPM (85%): ~500</li>
<li style="margin-left: 20px;">Agree to participate (80%): 400 randomized (100 per arm)</li>
</ul>
</div></details>
<details><summary><strong>2.4 Attrition Planning</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Over-recruit by <strong>20%</strong> to allow for dropout</li>
<li style="margin-left: 0px;">Begin with N = 100 per condition, end with N = 80 completing</li>
<li style="margin-left: 0px;">Starting Month 6: recruit <strong>11 participants per month</strong> throughout recruitment period</li>
<li style="margin-left: 0px;"><strong>Retention strategies</strong>:</li>
<li style="margin-left: 20px;">Financial incentive for study completion</li>
<li style="margin-left: 20px;">Request names/addresses/telephone numbers of three contacts for locating participants if missed appointment</li>
</ul>
</div></details>
<details><summary><strong>2.5 Eligibility Criteria</strong></summary><div style="padding-left: 20px;">
<p><strong>Inclusion Criteria</strong>:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Aged 18+ years</li>
<li style="margin-left: 0px;">Screening BP &lt;140/90 mmHg</li>
</ul>
<p><strong>Exclusion Criteria</strong>:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Unable to comply with protocol</li>
<li style="margin-left: 0px;">Participation in any other HTN-related clinical trial</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Sample Size, Power Analysis, and Statistical Approach</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Power Analysis: 8-Week Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Design</strong>: 4 arms, 80 subjects completing per arm</li>
<li style="margin-left: 0px;">Assumed within-group SD: <strong>13 mmHg</strong></li>
<li style="margin-left: 0px;">Standardized effect size (f): <strong>0.26</strong> (medium effect)</li>
<li style="margin-left: 0px;">Power for overall ANOVA: <strong>0.98</strong> at α = 0.05</li>
</ul>
</div></details>
<details><summary><strong>3.2 Specific Comparisons at 8 Weeks</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Comparison</th>
<th>Expected SBP Change</th>
<th>Cohen&#x27;s d</th>
<th>Power</th>
</tr></thead>
<tbody>
<tr>
<td>Intervention + placebo vs. UC</td>
<td>8 mmHg (intervention) vs. 2 mmHg (UC)</td>
<td>0.32</td>
<td>0.84</td>
</tr>
<tr>
<td>Intervention vs. placebo</td>
<td>10 mmHg vs. 5 mmHg</td>
<td>0.36</td>
<td>0.89</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">First comparison tests device effect (guided breathing or placebo) relative to UC</li>
<li style="margin-left: 0px;">Second comparison establishes intervention effect relative to placebo device</li>
</ul>
</div></details>
<details><summary><strong>3.3 Power Analysis: 12-Month Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Placebo and UC groups expected to have 2 mmHg SBP change at 12 months</li>
<li style="margin-left: 0px;">Placebo group combined with UC (N = 160)</li>
<li style="margin-left: 0px;"><strong>Extended intervention</strong>: maintain 10 mmHg decrease at 12 months</li>
<li style="margin-left: 0px;"><strong>Standard intervention</strong>: partially maintain effect—6.6 mmHg decrease after 12 months</li>
<li style="margin-left: 0px;">Overall ANOVA effect size: f = 0.19, power: <strong>0.86</strong></li>
</ul>
</div></details>
<details><summary><strong>3.4 Specific Comparisons at 12 Months</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Comparison</th>
<th>Expected SBP Change</th>
<th>Cohen&#x27;s d</th>
<th>Power</th>
</tr></thead>
<tbody>
<tr>
<td>Intervention (Standard + Extended) vs. UC</td>
<td>8 mmHg vs. 2 mmHg</td>
<td>0.18</td>
<td>0.77</td>
</tr>
<tr>
<td>Extended vs. Standard Intervention</td>
<td>10 mmHg vs. 3.3 mmHg</td>
<td>0.41</td>
<td>0.83</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>3.5 Statistical Analysis Approach</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary analyses</strong>: intention-to-treat with baseline observations carried forward for non-completers</li>
<li style="margin-left: 0px;"><strong>Method</strong>: One-way ANOVA on change scores (baseline to 8 weeks for primary aim; baseline to 12 months for secondary aim)</li>
<li style="margin-left: 0px;"><strong>Power and sample size</strong> based on this analytic strategy</li>
</ul>
</div></details>
<details><summary><strong>3.6 Preliminary Analyses and Data Preparation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Screen all variables for inconsistent/abnormal values</li>
<li style="margin-left: 0px;">Assess continuous measures for skewness and outliers</li>
<li style="margin-left: 0px;">Use transformations to reduce heteroscedasticity and extreme value effects</li>
<li style="margin-left: 0px;">Use exploratory graphical methods to assess transformation effects on linearity</li>
</ul>
</div></details>
<details><summary><strong>3.7 Missing Data Handling</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Assess missing data rates and patterns by treatment group</li>
<li style="margin-left: 0px;"><strong>Primary analyses</strong>: intention-to-treat with carry-forward</li>
<li style="margin-left: 0px;"><strong>Secondary measures</strong> (including questionnaires):</li>
<li style="margin-left: 20px;">Maximum likelihood estimation for scattered missing responses</li>
<li style="margin-left: 20px;">Assessment of correlates of &quot;missingness&quot;</li>
<li style="margin-left: 20px;">Complete case analysis</li>
<li style="margin-left: 0px;">Tabulate reasons for withdrawal/loss to follow-up by experimental group</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Measures, Procedures, and Review Criteria</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Measures Categories</strong></summary><div style="padding-left: 20px;">
<p><strong>Three categories</strong>:</p>
<p>1. Self-report measures</p>
<p>2. Physiological measures taken in laboratory</p>
<p>3. Ambulatory physiological measures</p>
</div></details>
<details><summary><strong>4.2 Self-Report Measures</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Measure</th>
<th>Purpose</th>
<th>Timing</th>
</tr></thead>
<tbody>
<tr>
<td>NYMC demographic form</td>
<td>Baseline characteristics</td>
<td>Screening</td>
</tr>
<tr>
<td>Branson self-report adherence questionnaire</td>
<td>Medication adherence assessment</td>
<td>Baseline, 8 weeks, 12 months</td>
</tr>
<tr>
<td>Current medications (from patient vials)</td>
<td>Medication tracking</td>
<td>Screening, baseline</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>4.3 Branson Medication Adherence Questionnaire</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Well-validated 6-item scale for antihypertensive medication adherence</li>
<li style="margin-left: 0px;">Used in other hypertensive patient studies</li>
<li style="margin-left: 0px;"><strong>Cronbach&#x27;s alpha</strong>: 0.9 (high reliability)</li>
<li style="margin-left: 0px;">Helps interpret intervention effects on BP control</li>
</ul>
</div></details>
<details><summary><strong>4.4 Physiological Measures: Ambulatory Blood Pressure (ABP)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Device</strong>: Kaplan model 1234 ABP monitor (validated, Pomona, CA)</li>
<li style="margin-left: 0px;">Validation procedure:</li>
<li style="margin-left: 20px;">Simultaneous readings by monitor and trained RA</li>
<li style="margin-left: 20px;">T-connector with mercury sphygmomanometer and stethoscope</li>
<li style="margin-left: 20px;">Mean agreement must be within <strong>5 mmHg</strong> for successful validation</li>
<li style="margin-left: 0px;">Subject instructions for reading failures (usually arm movement)</li>
<li style="margin-left: 0px;">Failed reading: monitor makes one attempt 2 minutes later</li>
<li style="margin-left: 0px;">Subjects given telephone number for investigator/technician contact</li>
</ul>
</div></details>
<details><summary><strong>4.5 Chart Measures</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conduct chart review at discharge to abstract:</li>
<li style="margin-left: 20px;">Comorbidities</li>
<li style="margin-left: 20px;">Antihypertensive medication changes</li>
<li style="margin-left: 0px;">Purpose: assist in interpretation of BP outcome</li>
<li style="margin-left: 0px;"><strong>Quality control</strong>: Random sample of 20% reviewed by second coder (blind to first coder&#x27;s ratings)</li>
<li style="margin-left: 0px;">Calculate interjudge reliability</li>
</ul>
</div></details>
<details><summary><strong>4.6 Randomization Procedures</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Follow <strong>CONSORT guidelines</strong> for clinical trial reporting</li>
<li style="margin-left: 0px;"><em></em>Unit of</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Measures, Procedures, and Review Criteria (Continued)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.6 Randomization Procedures</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Follow <strong>CONSORT guidelines</strong> for clinical trial reporting</li>
<li style="margin-left: 0px;"><strong>Unit of randomization</strong>: Individual</li>
<li style="margin-left: 0px;"><strong>Allocation schedule generation</strong>: Dr. McBurney (project statistician) generates random numbers, places assignments in sealed envelopes</li>
<li style="margin-left: 0px;"><strong>Allocation concealment</strong>: Randomly sized blocks prevent project staff from anticipating group assignment by process of elimination</li>
<li style="margin-left: 0px;"><strong>Separation of generator and executor</strong>: Sequence held by Dr. McBurney or data manager in Queens, NY (off-site); project staff contact by phone when ready to randomize</li>
<li style="margin-left: 0px;">Access limited: nobody connected with trial conduct has access to randomization records</li>
<li style="margin-left: 0px;">Dr. McBurney&#x27;s office maintains record of assignments and verifies correct group analysis</li>
</ul>
</div></details>
<details><summary><strong>4.7 Personnel and Their Roles</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Research Assistants (RAs)</strong>: Conduct screenings, patient scheduling, consent, enrollment procedures, chart reviews</li>
<li style="margin-left: 0px;"><strong>Supervision</strong>: RAs supervised by Dr. Okata</li>
</ul>
</div></details>
<details><summary><strong>4.8 Reminder Telephone Call Procedure</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Eligible participants given appointment for initial visit</li>
<li style="margin-left: 0px;">Receive phone call night before appointment</li>
<li style="margin-left: 0px;">Illustrates level of detail needed—anticipate every conceivable problem and incorporate methodological procedure to address it</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Intervention Description, Control Conditions, and Potential Confounders</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Device Details</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Manufacturer</strong>: Acme, Inc., Paramus, NJ</li>
<li style="margin-left: 0px;">Guides participants to reduce breathing rate to 6 breaths/minute</li>
</ul>
</div></details>
<details><summary><strong>5.2 Control Conditions Description</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Placebo device identical in appearance to intervention device</li>
<li style="margin-left: 0px;">Exception: does not guide to 6–10 breaths/minute; plays random musical tones instead</li>
<li style="margin-left: 0px;">Creates 15-minute relaxation period (control for relaxation effect on BP)</li>
<li style="margin-left: 0px;">Placebo device use ends at 8 weeks</li>
</ul>
</div></details>
<details><summary><strong>5.3 Potential Confounding: Medication Changes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Concern</strong>: In intervention group, improvement predicted; control condition participants may receive additional treatment from physicians</li>
<li style="margin-left: 0px;"><strong>Minimization strategies</strong>:</li>
<li style="margin-left: 20px;">At screening: inform participants their BP is higher than recommended</li>
<li style="margin-left: 20px;">RA suggests they see a physician</li>
<li style="margin-left: 20px;">If planning to see physician for treatment: not admitted immediately, only after physician visit</li>
<li style="margin-left: 20px;">If new treatment prescribed (new medications or increased dosages): wait 2 months, then rescreen to allow stabilization</li>
<li style="margin-left: 20px;">Depending on results: may be admitted to study</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Adherence Monitoring and Study Timetable</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Participant Burden by Condition</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Standard intervention and placebo conditions</strong>: Use device 4 days/week for 8 weeks</li>
<li style="margin-left: 0px;"><strong>Extended duration condition</strong>: Use device 4 days/week for 12 months</li>
<li style="margin-left: 0px;"><strong>All participants</strong>: Take BP 2 days/week for 12 months (three readings each time)</li>
<li style="margin-left: 0px;"><strong>Burden assessment</strong>: Large burden, especially for extended duration condition</li>
</ul>
</div></details>
<details><summary><strong>6.2 Automatic Device Monitoring</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Guided breathing and placebo devices automatically record:</li>
<li style="margin-left: 20px;">Date, time, duration of sessions</li>
<li style="margin-left: 20px;">Statistics regarding performance in &lt;10 breath/minute range</li>
<li style="margin-left: 0px;">Home BP device stores readings with dates and times</li>
</ul>
</div></details>
<details><summary><strong>6.3 Adherence Data Utilization</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Device data used in sub-analyses to examine effects of amount of practice on:</li>
<li style="margin-left: 20px;">Change in BP</li>
<li style="margin-left: 20px;">HRV and baroreflex sensitivity</li>
</ul>
</div></details>
<details><summary><strong>6.4 Study Timetable Example (3-Year Human Study)</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Year</th>
<th>Quarter</th>
<th>Activity</th>
</tr></thead>
<tbody>
<tr>
<td>1</td>
<td>1st</td>
<td>Setup/Hiring</td>
</tr>
<tr>
<td>1</td>
<td>2nd</td>
<td>Training</td>
</tr>
<tr>
<td>1</td>
<td>3rd</td>
<td>Screening/Enrollment, Cohort 1 Baseline</td>
</tr>
<tr>
<td>1</td>
<td>4th</td>
<td>Cohort 2–4 Baseline</td>
</tr>
<tr>
<td>2</td>
<td>1st</td>
<td>Cohort 5–6 Baseline, Cohort 4 Follow-Up</td>
</tr>
<tr>
<td>2</td>
<td>2nd</td>
<td>Cohort 5 Follow-Up</td>
</tr>
<tr>
<td>2</td>
<td>3rd</td>
<td>Data analysis, Report Writing</td>
</tr>
<tr>
<td>2</td>
<td>4th</td>
<td>(Continue analysis)</td>
</tr>
<tr>
<td>3</td>
<td>All</td>
<td>Analysis and dissemination</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Study: 180 subjects, seen at baseline and 6-month follow-up</li>
<li style="margin-left: 0px;">Schedule: 30 per quarter (10 per month)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. NIH Review Criteria</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Significance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Addresses important <strong>public health problem</strong>: excess morbidity, mortality, and economic burden due to uncontrolled hypertension (HTN)</li>
<li style="margin-left: 0px;"><strong>Scientific gains if aims achieved</strong>:</li>
<li style="margin-left: 20px;">Better understanding of role of characteristic breathing patterns and respiratory sinus arrhythmia (RSA) in BP regulation</li>
<li style="margin-left: 20px;">Understanding non-pharmacological approaches to HTN treatment as supplement or alternative to pharmacological therapy</li>
</ul>
</div></details>
<details><summary><strong>7.2 Approach</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>RCT design</strong>: powerful, provides important scientific information concerning causal relation between intervention and outcome</li>
<li style="margin-left: 0px;">Provides feasibility and utility information about proposed intervention</li>
<li style="margin-left: 0px;"><strong>Measures</strong>: Based on assessment of current literature—most useful, cutting-edge techniques:</li>
<li style="margin-left: 20px;">Ambulatory assessment of BP and respiration</li>
<li style="margin-left: 0px;"><strong>Statistical analyses</strong>: Use cutting-edge techniques</li>
<li style="margin-left: 0px;">Alternative research strategies and rationales for methodological decisions described (e.g., design considerations like crossover rejection)</li>
</ul>
</div></details>
<details><summary><strong>7.3 Innovation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Represents innovative treatment intervention</li>
<li style="margin-left: 0px;">Departure from traditional HTN treatment consideration</li>
<li style="margin-left: 0px;">Potentially important advancement in public health</li>
</ul>
</div></details>
<details><summary><strong>7.4 Investigators: Team Expertise</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Research team has done seminal work in:</li>
<li style="margin-left: 20px;">BP measurement</li>
<li style="margin-left: 20px;">Psychosocial causes of essential hypertension</li>
<li style="margin-left: 20px;">Behavioral interventions for HTN treatment</li>
<li style="margin-left: 0px;">Extensive experience in conduct of behavioral clinical trials</li>
</ul>
</div></details>
<details><summary><strong>7.5 Institutional Resources and Support</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>NYMC</strong>: Strong institutional support for research over past several years</li>
<li style="margin-left: 0px;"><strong>Resources available</strong>:</li>
<li style="margin-left: 20px;">Research space</li>
<li style="margin-left: 20px;">Computer and Internet resources</li>
<li style="margin-left: 20px;">Clinical needs: ABP monitors, Holter monitors, ambulatory respiratory assessment monitors</li>
<li style="margin-left: 0px;"><strong>Patient population</strong>: Diverse, largely economically disadvantaged—need non-pharmacological treatments</li>
<li style="margin-left: 0px;">Large patient load with substantial minority representation with poorly controlled HTN</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Dissemination of Results</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Publication and Conference Schedule</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Timeline</th>
<th>Deliverable</th>
</tr></thead>
<tbody>
<tr>
<td>End of Year 1</td>
<td>Submit methods/baseline paper to <em>Controlled Clinical Trials</em></td>
</tr>
<tr>
<td>End of Year 2</td>
<td>Present preliminary findings at national conference</td>
</tr>
<tr>
<td>End of Year 3</td>
<td>Present interim findings at national conference; publish findings</td>
</tr>
<tr>
<td>End of Year 4</td>
<td>Present further findings at national conference</td>
</tr>
<tr>
<td>End of Year 5</td>
<td>Present first set of basic results at national conference; publish findings</td>
</tr>
<tr>
<td>Middle of Year 6</td>
<td>Present at national conference; publish extensive findings concerning clinical outcomes and mechanisms</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>8.2 Importance of Dissemination Planning</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Often overlooked in proposals</li>
<li style="margin-left: 0px;">Talks and papers are the only product for NIH investment</li>
<li style="margin-left: 0px;">Make dissemination intentions specific</li>
<li style="margin-left: 0px;">Helps justify travel money requested (see Chapter 7)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Key Methodological Principles and Hints</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Writing Principles</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Revise repeatedly</strong>: Every time you open the file, read with goal of cutting—no matter how carefully written</li>
<li style="margin-left: 0px;">Don&#x27;t always start at beginning—may end with finely crafted beginning but weak middle/ending</li>
<li style="margin-left: 0px;">Focused editing forces careful word choice</li>
<li style="margin-left: 0px;">Every word should be there for a reason (like poetry)</li>
<li style="margin-left: 0px;">Hear sentence in head—are connections still there? Is meaning clear?</li>
</ul>
</div></details>
<details><summary><strong>9.2 Getting Feedback</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Read stuff out loud to others</li>
<li style="margin-left: 0px;">They will hear something missed</li>
<li style="margin-left: 0px;">May receive feedback that story is out of order, paragraph needs moving, or content unclear</li>
</ul>
</div></details>
<details><summary><strong>9.3 Statistical Citation Guidelines</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Simple statistics (t-tests, correlations, ANOVA, regressions): no citations needed</li>
<li style="margin-left: 0px;">Complex procedures (MANOVA, simultaneous equation modeling, hierarchical modeling): provide references</li>
<li style="margin-left: 0px;">Controversial procedures: provide references for validity</li>
</ul>
</div></details>
<details><summary><strong>9.4 Avoiding Type I Error (Fishing Expeditions)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Reviewers jump on proposals appearing to capitalize on chance</li>
<li style="margin-left: 0px;">Strongly justified hypothesis → Type I error less of an issue (but always an issue)</li>
<li style="margin-left: 0px;"><strong>Multiple outcome measures</strong>: Make specific predictions for each</li>
<li style="margin-left: 0px;">If only one/two show predicted effect: is that sufficient to say hypothesis supported?</li>
<li style="margin-left: 0px;">No specific hypotheses about each outcome: use statistical controls</li>
<li style="margin-left: 0px;">Greater problem with exploratory hypotheses vs. primary well-grounded hypotheses</li>
</ul>
</div></details>
<details><summary><strong>9.5 Junior Investigator Considerations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">NIH interested in encouraging junior investigators</li>
<li style="margin-left: 0px;">NI (New Investigator) or ESI (Early Stage Investigator) status provides &quot;handicap&quot; advantage</li>
<li style="margin-left: 0px;">Some grant mechanisms: attain lesser score (vs. senior investigators) to reach funding range</li>
</ul>
</div></details>
<details><summary><strong>9.6 Anticipating Reviewer Concerns</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Think like reviewer—identify where doubt might occur</li>
<li style="margin-left: 0px;">Cleverly undermine possible effect by showing anticipation and allaying concern before it occurs</li>
<li style="margin-left: 0px;">If weakness cannot be avoided (due to patient population characteristic, assay that doesn&#x27;t exist): describe conundrum at exact point where reviewer will spot it</li>
<li style="margin-left: 0px;">Explain why chosen</li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
